Speakers will outline critical steps needed to achieve health equity
Published 08-22-22
Submitted by Illumina
Originally published on Illumina News Center
SAN DIEGO, August 22, 2022 /CSRwire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health. In addition, IGF will host a panel session titled "Making 'Genomics for All' More than a Mantra," on the requirements needed to ensure broader access to genomic health.
"Genomics should be available to the many, not the few, and even though the genomic health era has already led to breakthrough discoveries that are advancing medical care, the benefits have not yet had a true globalimpact," said Kathryne Reeves, chief marketing officer for Illumina. "Through sessions led by Bill Gates and expert panelists, Illumina Genomics Forum will help attendees see and understand the path toward global health equity."
The "Genomics for All" panel includes representatives driving increased access to genomic health, including:
Illumina previously announced that former U.S. President Barack Obama will headline the inaugural forum in a fireside chat on the evening of Wednesday, September 28. Twelve years after the passage of the Affordable Care Act, Obama will discuss the continued need for equity, accessibility, and smarter healthcare to improve the human condition. Additional speakers, panels, and details about the event agenda will continue to be released in the coming weeks.
Other IGF key themes include:
IGF will take place in San Diego from September 28 through October 1. For more information and to register for the conference, go to illuminagenomicsforum.com.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Adi Raval
US: 202-629-8172
PR@illumina.com
SOURCE Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
More from Illumina